ARTICLE | Clinical News
Mylotarg gemtuzumab ozogamicin regulatory update
June 28, 2010 7:00 AM UTC
Pfizer will withdraw Mylotarg gemtuzumab at the request of FDA after the cancer drug plus chemotherapy did not demonstrate improved survival and produced a significantly higher rate of fatal induction...